Clinical Trial: A Study of DS5361b in Participants With Advanced Solid Tumors

U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07182591) titled 'A Study of DS5361b in Participants With Advanced Solid Tumors' on Aug. 27.

Brief Summary: This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or metastatic solid tumors.

Study Start Date: Sept. 10

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor

Intervention: DRUG: DS5361b

Dose Escalation Part: DS5361b will be administered at escalating doses to determine the RDE.

Dose Expansion Part: DS5361b will be administered at RDE.

DRUG: Pembrolizumab

Dose Escalation Part: Pembrolizum...